How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

998 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Cause of Androgenic Alopecia: Crux of the Matter Full Text available with Trip Pro

Cause of Androgenic Alopecia: Crux of the Matter What is wrong with the current understanding of etiopatho genesis of androgenic alopecia (AGA)? What is the most important question to ask to understand AGA? Why is that question skimped? Which findings are interpreted incorrectly? Is there anything that has not been discerned about AGA until today? What are the deceptive factors for investigators? Is it possible to snap the whole view uninterruptedly in one clear picture? Answers and an overview

2013 Plastic and Reconstructive Surgery Global Open

102. Use of body and beard donor hair in surgical treatment of androgenic alopecia Full Text available with Trip Pro

Use of body and beard donor hair in surgical treatment of androgenic alopecia Follicular unit transplant is a widely used surgical treatment for androgenic alopecia. However, for patients with extensive hair loss (Norwood 5 and above), scalp donor hair are not sufficient to cover all areas of baldness. This study aims to assess suitability of beard and body donor hair when transplanted to the scalp.In 35 male patients having varying degrees of androgenic alopecia, body and beard donor hair were (...) for treating androgenic alopecia. These hairs, however, do not change their colour, curl, and shaft diameter (calibre). Thus, proper planning is a must when using the different types of donor hair for transplanting.

2013 Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India

103. Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study. Full Text available with Trip Pro

Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study. The variable success of topical minoxidil in the treatment of androgenic alopecia has led to the hypothesis that other pathways could mediate this form of hair loss, including infection and/or microinflammation of the hair follicles. In this study, we prepared a multimodal microemulsion comprising minoxidil (a dihydrotestosterone (...) ) slowed hair loss, increased hair growth, and improved appearance, and showed no appreciable side effects, such as itching and/or inflammation of the scalp compared with the minoxidil alone and placebo formulations. These improvements were in agreement with the photographic assessments made by the investigators. Formula A was shown to be an o/w formulation with consistent pH, viscosity, specific gravity, and homogeneity, and was physically stable after 24 months of normal storage.A multimodal

2013 Drug design, development and therapy Controlled trial quality: uncertain

104. Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03543189 Recruitment Status : Recruiting

2018 Clinical Trials

105. Androgens in Women: Hormone modulating therapies for skin disease (Part II). (Abstract)

Androgens in Women: Hormone modulating therapies for skin disease (Part II). Androgen-mediated cutaneous disorders (AMCDs) in women including acne, hirsutism, and female pattern hair loss (FPHL) can be treated with hormone-modulating therapies. In the second part of this Continuing Medical Education series, we discuss the hormone-modulating therapies available to dermatologists for the treatment of AMCDs including combined oral contraceptives, spironolactone, finasteride, dutasteride (...) , and flutamide. Available hormone-modulating treatments utilized for each AMCDs are reviewed, along with mechanisms of androgen modulation, safety profile, contraindications, monitoring parameters, and evidence of efficacy. Medications discussed include ones that are FDA-approved for certain AMCDs as well as some that are used off-label. Despite the ubiquity of hormone-modulating therapies used for AMCDs, this review highlights the need for more rigorous studies to evaluate these therapies for acne

2018 Journal of American Academy of Dermatology

106. COMbination of Bipolar Androgen Therapy and Nivolumab

COMbination of Bipolar Androgen Therapy and Nivolumab COMbination of Bipolar Androgen Therapy and Nivolumab - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. COMbination of Bipolar Androgen Therapy (...) Cancer Center at Johns Hopkins Collaborator: Bristol-Myers Squibb Information provided by (Responsible Party): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Study Details Study Description Go to Brief Summary: Single arm, multicenter, open-label Phase II study of the effects of parenteral testosterone in combination with nivolumab in men with metastatic castration-resistant prostate cancer who previously progressed on at least one novel androgen-receptor targeted therapy (i.e

2018 Clinical Trials

107. Prostaglandin D2-Mediated DP2 and AKT Signal Regulate the Activation of Androgen Receptors in Human Dermal Papilla Cells Full Text available with Trip Pro

Prostaglandin D2-Mediated DP2 and AKT Signal Regulate the Activation of Androgen Receptors in Human Dermal Papilla Cells Prostaglandin D2 (PGD2) and prostaglandin D2 receptor 2 (DP2) is known to be an important factor in androgenetic alopecia (AGA). However, the effect of PGD2 in human dermal papilla cells (hDPCs) is not fully understood. The function of PGD2-induced expression of the androgen receptor (AR), DP2, and AKT (protein kinase B) signal were examined by using real time-PCR (qRT-PCR

2018 International journal of molecular sciences

108. Androgen Therapy in Women Full Text available with Trip Pro

androgens result in deleterious clinical consequences? Experimental models to investigate this question include both large observational studies to examine correlations between androgen levels and clinical observations as well as small, randomized, placebo-controlled studies that examine the effects of androgen therapy in women with a defined cause of androgen deficiency, eg, bilateral oophorectomy or hypopituitarism. It remains unclear whether androgen deficiency due to a defined cause, ie, loss (...) postmenopausal period ( ). The effects of low-dose androgen administration with or without estrogens on BMD have been studied in several conditions known to be associated with bone loss, including menopause, anorexia nervosa, and hypopituitarism. Studies have been limited by their small size and short duration. In a small, randomized, placebo-controlled study in women with hypopituitarism and severe androgen deficiency, transdermal T administration (300 μg/d) increased BMD at the hip and radius

2014 The Endocrine Society

109. Androgenic Alopecia

. Differential Diagnosis IX. Grading: Rating of Hair Loss (Norwood and Hamilton Scale) Type I: Minimal hair line recession Type II: Symmetrical triangular over temples Type III: More at vertex and less at temple Type IV-V: Temple and vertex ; some crown loss Type VI: Contiguous frontal, vertex, and crown baldness Type VII: remains only over ears and occiput References Hamilton (1951) Ann NY Acad Dermatol 53:708-28 X. Labs: Women with Androgenetic Alopecia Indications (Not required in most cases) Irregular (...) : Androgenic Alopecia , Androgenetic Alopecia , Male-patterned Baldness From Related Chapters II. Definition Non-scarring androgen related III. Epidemiology Most common type of (esp. white men) Hereditary trait (positive ) Increasing with age Affects white men 30% at age 30, 40% at age 40, 50% at age 50 years Affects 38% of women over age 70 years IV. Course onset between ages 12 to 40 years evident by age 50 in >50% of patients V. Pathophysiology Androgen exposure shortens phase Men with increased

2015 FP Notebook

110. Alopecia, androgenetic - female

Alopecia, androgenetic - female Alopecia, androgenetic - female - NICE CKS Share Alopecia, androgenetic - female: Summary Androgenetic alopecia (or female pattern hair loss) describes a distinctive pattern of hair loss, which may occur in genetically predisposed women and is thought to be androgen dependent. Hair loss is usually diffuse and affects the top of the scalp. The underlying pathological process involves pigmented terminal hairs gradually being replaced by smaller, less pigmented (...) hairs similar to vellus hairs. The prevalence and severity of androgenetic alopecia in women increases greatly after the menopause and affects about a third of white women aged 70 years and older. Complications of androgenetic alopecia may include adverse psychosocial effects. Hair loss in women tends to progress over time, but the rate of progression is unpredictable. Women with androgenetic alopecia rarely go completely bald. The diagnosis is usually made from the history and clinical findings

2016 NICE Clinical Knowledge Summaries

111. Hair follicle stem cell differentiation is inhibited through a cross talk between Wnt/β-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. (Abstract)

Hair follicle stem cell differentiation is inhibited through a cross talk between Wnt/β-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. Hair follicle (HF) regeneration begins when signals from the mesenchyme-derived dermal papilla cells (DPC) reach multipotent epidermal stem cells in the bulge region. Wnt/β-catenin signalling is known to affect mammalian hair growth positively. In androgenetic alopecia (AGA), androgens cause HF miniaturization (...) through a mechanism that remains unclear. Circulating androgens act on DPC and alter paracrine factors that influence hair epithelial cells.To elucidate the role of androgens in dermal papilla-induced differentiation of HF stem cells.HF stem cell differentiation was evaluated in a coculture model with DPC or culturing with media conditioned by DPC after activation of androgen and Wnt/β-catenin signalling pathways. To study the molecular cross-talk between the androgen and Wnt signalling pathway in DPC

2012 British Journal of Dermatology

112. Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss

Information Go to Layout table for additonal information Responsible Party: Family Marketing ClinicalTrials.gov Identifier: Other Study ID Numbers: ProHair01 First Posted: May 29, 2014 Last Update Posted: July 18, 2017 Last Verified: July 2017 Keywords provided by Family Marketing: Androgenetic Alopecia Male Baldness hair loss pattern Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical (...) Details Study Description Go to Brief Summary: HCap Formula is composed of medicinal plants, vitamins and minerals. The purpose of this study is to evaluate the efficacy of HCap Formula, a nutrition supplement for promoting hair growth in men with tendencies for hair loss. Condition or disease Intervention/treatment Phase Androgenetic Alopecia Dietary Supplement: HCap Formula Dietary Supplement: Placebo Phase 2 Detailed Description: This study consists of a treatment phase (6 months) and a follow-up

2014 Clinical Trials

113. Weight Loss and Lowering Androgens Predict Improvements in Health-Related Quality of Life in Women With PCOS. Full Text available with Trip Pro

Weight Loss and Lowering Androgens Predict Improvements in Health-Related Quality of Life in Women With PCOS. Polycystic ovary syndrome (PCOS) is associated with reduced health-related quality of life (HRQOL) and increased prevalence of depressive and anxiety disorders. The impact of PCOS-specific treatments on these co-morbidities is unclear.To assess the impact of weight loss and decreasing hyperandrogenism on HRQOL and mood and anxiety disorders in women with PCOS.A secondary analysis (...) in the weight domain (P < .001) and physical well-being (P < .02), change in T correlated with improvements in the hair domain (P < .001), and change in both weight and T correlated with the infertility (P < .001) and menstrual domains (P < .05).Both weight loss and OCP use result in significant improvements in several physical and mental domains related to quality of life, depressive symptoms, and anxiety disorders, and combined therapies offer further benefits in overweight/obese women with PCOS.

2017 The Journal of clinical endocrinology and metabolism Controlled trial quality: predicted high

114. Androgens trigger different growth responses in genetically identical human hair follicles in organ culture that reflect their epigenetic diversity in life Full Text available with Trip Pro

: some remain unaffected ( e.g., eyelashes) or are inhibited, causing balding. How sex steroid hormones alter such developmental processes is unclear, despite high incidences of hormone-driven cancer, hirsutism, and alopecia. Unfortunately, existing development models are not androgen sensitive. Here, we use hair follicles to establish an androgen-responsive human organ culture model. We show that women's intermediate facial follicles respond to men's higher androgen levels by synthesizing more hair (...) Androgens trigger different growth responses in genetically identical human hair follicles in organ culture that reflect their epigenetic diversity in life Male sex hormones-androgens-regulate male physique development. Without androgen signaling, genetic males appear female. During puberty, increasing androgens harness the hair follicle's unique regenerative ability to replace many tiny vellus hairs with larger, darker terminal hairs ( e.g., beard). Follicle response is epigenetically varied

2017 The FASEB Journal

115. Study on Androgen Receptor and Triple Negative Breast Cancer

Study on Androgen Receptor and Triple Negative Breast Cancer Study on Androgen Receptor and Triple Negative Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study on Androgen Receptor (...) Information provided by (Responsible Party): UNICANCER Study Details Study Description Go to Brief Summary: This is a multicenter uncontrolled, open-label, prospective, non-comparative randomized, phase II study. Patients will be randomized between darolutamide in Arm n°1 (two-stage Simon's design) and capecitabine in Arm n°2 with two patients randomized in Arm n°1 for one patient randomized in Arm n°2. The trial population is composed of women over 18 years old with triple-negative and androgen receptor

2017 Clinical Trials

116. Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has

2017 Clinical Trials

117. A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss

of hormone therapy within 6 months prior to entering study Hormone therapy with androgenic action, e.g. norethisterone etc. Pregnancy or lactation within 6 months prior to entering study Alopecia areata Scarring alopecia Treatment with hair promoting agent within 3 months prior to entering study Known hair loss after drug intake Concomitant use of the drugs causing a hair loss (e.g. aromatase inhibitors, thyreostatics, cytostatics, etc,) Contacts and Locations Go to Information from the National Library (...) as for the treatment of damaged hair, in the combined therapy can be successfully applied in other types of alopecia. The purpose of this study is to evaluate efficacy and tolerability of combination therapy Pantovigar plus 2% minoxidil vs 2% minoxidil. To collect tolerability data for combined treatment Pantovigar plus 2% Minoxidil course therapy. Condition or disease Intervention/treatment Phase Female Pattern Hair Loss Androgenetic Alopecia (AGA) Ludwig Type 1 Ludwig Type 2 Drug: Pantovigar Drug: Minoxidil 2

2013 Clinical Trials

118. Androgen Replacement in Women

libido and sexual satisfaction Improves sense of well-being Appears to improve concentration and memory VII. Adverse Effects abnormalities (associated with oral androgens) tumors Cholestatic Iatrogenic Irreversible effects (Male patterned baldness) Voice deepening Clitoromegaly Reversible effects and oily skin (facial hair) Adverse effect on lipid profile Increases Decreases VIII. Causes: Secondary Causes of Hypoandrogenism Hypopituitarism Oophorectomy Secondary Medications lowering androgen levels (...) Androgen Replacement in Women Androgen Replacement in Women Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Androgen Replacement

2018 FP Notebook

119. Factors associated with female pattern hair loss and its prevalence in Taiwanese women: A community-based survey. (Abstract)

Factors associated with female pattern hair loss and its prevalence in Taiwanese women: A community-based survey. Although female pattern hair loss (FPHL) has been considered simply the female counterpart of male pattern hair loss in men, the risk factors may differ.We sought to evaluate factors associated with FPHL and to estimate its prevalence in women.In total, 26,226 subjects aged 30 years and older participated in a cross-sectional survey. Ludwig and Norwood classifications were used (...) to assess the degree of hair loss. Information on possible risk factors for FPHL was collected using a questionnaire interview.The prevalence of FPHL (Ludwig grade >I) for all ages was 11.8% (95% CI 11.5%-12.2%), increasing with advancing age. After controlling for age and family history, statistically significant associations were noted between FPHL and high fasting glucose (odds ratio [OR] 1.15, 95% confidence interval [CI] 1.04-1.28), fewer childbirths (OR 1.24, 95% CI 1.12-1.38), breast-feeding

2012 Journal of American Academy of Dermatology

120. Selected variants of the steroid-5-alpha-reductase isoforms SRD5A1 and SRD5A2 and the sex steroid hormone receptors ESR1, ESR2 and PGR: No association with female pattern hair loss identified. (Abstract)

Selected variants of the steroid-5-alpha-reductase isoforms SRD5A1 and SRD5A2 and the sex steroid hormone receptors ESR1, ESR2 and PGR: No association with female pattern hair loss identified. Female pattern hair loss (FPHL) is a common disorder with a complex mode of inheritance. Although understanding of its etiopathogenesis is incomplete, an interaction between genetic and hormonal factors is assumed to be important. The involvement of an androgen-dependent pathway and sex steroid hormones

2012 Experimental Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>